A B S T R A C T A gonococcal pilus vaccine or placebo was injected subcutaneously or intramuscularly into 71 human volunteers. The vaccine was found to be safe. The principal adverse reaction was a complaint ofa sore arm, which was caused, at least in part, to the volume of material injected. 6 of 64 (9%) volunteers receiving the larger doses also complained of malaise. The vaccine was found to be antigenic. All of the volunteers developed an immunoglobulin class-specific antibody response as measured by a solid phase radioimmunoassay. The antibody was capable of blocking the attachment of gonococci to epithelial cells. A slight antibody response was also demonstrated to gonococcal lipopolysaccharide but the antibody responsible for blocking attachment of gonococci was directed entirely at the pilus protein. The stimulated antibodies were shown to crossreact with isolated pili of heterologous gonococcal strains and to block the attachment of heterologous gonococci. Absorption of immune sera by a heterologous pilus reduced the inhibition of attachment antibodies to the pre-immune level, suggesting that the immune response was directed at a common pilus determinant.
INTRODUCTION
Gonorrhea is the most frequently reported communicable disease in the United States. Over 1 milThis work was presented in part at the Interscience Conference on Antimicrobia Agents and Chemotherapy/International Congress of Chemotherapy, Boston, Mass., 2 October
1979.
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J. Clin. Invest. The American Society for Clinical Investigai lion cases were reported in 1979 and it is estimated that at least an equal number of cases were not reported (1) . The methods of education, contact tracing, and early treatment presently used to control the spread of gonorrhea have proved not to be entirely effective. Furthermore, gonococcal pelvic inflammatory disease or salpingitis is associated with a significant incidence of recurrence, infertility, and ectopic pregnancy (2, 3 ). An effective vaccine would offer promising additional means of controlling this illness.
The description ofvirulent colony types ofgonococci by Kellogg and his colleagues (4) provided a major clue to the pathogenesis of gonorrhea. The most striking difference in the organisms making up the virulent colonies was the presence of pili (5) .
Gonococcal pili are protein filaments of -20,000 daltons that extend out from the cell wall (6) . They have been shown to be the principle mediators of attachment of gonococci to mammalian cells (6) (7) (8) , may contribute to the organisms ability to resist phagocytosis (9) (10) (11) (12) (13) (14) (15) , and may be involved in surface translocation by twitching motility (6) . Antibodies to pili have been demonstrated in patients with gonorrhea (16) and they have been shown to block the attachment of gonococci to human mucosal cells (17) .
Pili have been isolated and purified as a potential vaccine candidate (6, 18) and in preliminary studies in a limited number of volunteers have been shown to be safe and antigenic (6, 19) . This report describes the safety and antigenicity of a prototype gonococcal pilus vaccine, and demonstrates the ability of these antibodies to inhibit attachment of gonococci to buccal epithelial cells, a possible mechanism by which these antibodies might function to protect the host (17, 18) . METHODS Gonococcal pilus vaccine. The gonococcal pilus vaccine (Food and Drug Administration, Investigational New Drug Application 1351) was prepared at the University ofPittsburgh by Charles C. Brinton, Ph.D.1 (20) from gonococcal strain Pgh 3-2, originally isolated from the urethra of an infected male patient. Cloned piliated phase type 2 colonies of gonococci were harvested into phosphate-buffered saline (PBS) (pH 6.8) from the surface of solid GC medium (Difco Laboratories, Detroit, Mich.) enriched with defined supplement (4). The bacteria were collected by centrifugation (13,000 g for 30 min), and the supernate discarded. The organisms were resuspended in ethanolamine buffer (0.63 M, pH 10.5), and the pili sheared from them with a Waring blender (Waring Products Div., Dynamics Corp. of America, New Hartford, Conn.). The depiliated organisms were then sedimented by centrifugation (13,000 g for 30 min). The shearing and centrifugation steps were repeated and the pelleted organisms discarded. Pilus rods were crystallized from the supernate by the addition of 10% (vol/vol) saturated ammonium sulfate in ethanolamine buffer. Pili were collected by centrifugation. The purified pili, suspended in 0.01 M PBS (pH 6.8), were sterilized by membrane filtration (0.045 ,um millipore filters, Millipore Corp., Bedford, Mass.) and stored in vials containing 0.01% merthiolate as a preservative. The vaccine contained 0.855 mg/ml of pilus protein as determined by UV spectrophotometry (280 nm) and was kept at 40C until use (19) .
Criteria for purity. The criteria for purity of the vaccine preparation (Investigational New Drug Application 1351) were darkfield microscopy, electron microscopy, sodium dodecyl sulfate, polyacrylamide gel electrophoresis, UV absorption spectra and amino acid analysis. The tests were performed at the University of Pittsburgh. Darkfield microscopy revealed the presence of pilus crystals and the absence ofdetectable bacterial cells or other large particulates. Electron microscopy revealed only pilus crystals, single pili and a very small amount of pilus substructures and electron dense material. The ultraviolet spectrum was similar to that found with previous preparations of Pgh 3-2 pili (6) . A single main band of Coomassie Blue staining material was seen in the sodium dodecyl sulfate polyacrylamide gel at the expected position for N. gonorrhoeae Pgh 3-2 pili. When the appropriate plot was made of the positions of the standard proteins (bovine serum albumin: 68,000 daltons, ovalbumin: 43,000 daltons, papain: 23,000 daltons, myoglobin: 17,600 daltons, cytochrome c: 12,400 daltons) the molecular mass of the vaccine pilus band was determined to be 20,800 daltons. A very minor band at 40,300 daltons was also observed on the more heavily loaded gels. Densitometer tracings of the gel patterns show that this band compromised -3% of the total protein. It was felt that this band was a gonococcal pilin dimer since it appeared close to the position that would be expected for a dimer of GC pilin resulting from the alkaline conditions used in the purification and filtration ofthe vaccine. The amino acid analysis of the vaccine pili was sufficiently distinctive to allow it also to be used as a measure of purity and identity.
A Quantitation of antibody (micrograms per milliliter) was achieved by referenee to the formula described by Zollinger (21) xvhich was generated by a qiuanititative precipitin curve.
Inihibition of e)ithelial cell attachliment (IEA) (17 (17) .
Serutml adsorptiotn (17) . The LPS wvas bound to alum by mixinig 1 mg of LPS/ml vith 0.9 ml of 0.05 Ni aluminiumii hydroxide gel (0.05 MI AICl3 in NaOH, pH 6.6) at room temperature for 30 min. The LPS-alumil mixture was theni incubated wvith an eqtual volumine of 1% (wt/vol) BSA solutioni for 2 h at 37°C to bind the BSA to nonispecific sites on the alunm. The LPS-alum complex was sedlimlenited by centrifugation (12,000 g for 20 mIi) and washed twice with 0.15 M NaCI.
Prior to adsorption, the antigens were pelletedl by centrifugationi (purified piluis crystals, 13,000 g for 60 mIi; and LPS lbound to alumil, 12,000 g for 20 min). The pelletedl anitigeni (pili, 0.050 mg; LPS-alumil, 1 mig) vas resuspenided in 0.5 ml of serum. The antigen-serum mixture was incul)ated on a shaker apparatus at 37°C for 60 min andl then at 4°C for 60 min. The antigen-antib)ody comiplex was removedi by centriftugattioni as described al)ove.
The efficiency ofthe adsorption of gonococcal antibody was determined bv the SPRIA. Specific antigens were added until the amount of antibodv in the adsorbed secretioni that bound to a specific gonococcal antigeni had reached base-line levels.
Sertnmii (24); nucleic acid contamination was monitored by ultraviolet spectrophotometry (25) ; 2-keto-3-deoxy sugar concentration was determined by use of the method of Osborne (26) .
RESULTS
Adverse reactiois. The gonococcal vaccine was shown to be safe. 64 ofthe 71 volunteers (89%) returned the questioinnaires or were interviewed within 24 h of the initial vaccination. Soreness at the site of injection was the most common complaint and occurred in 50 of Table III .
Because of the recognized difficulty in the complete and absolute separation of bacterial cell wall proteins from LPS, the large amount of vaccine given, and the results of the limulus lysate that suggested LPS contamination, antibody to LPS was measured directly using the SPRIA. Two rabbits were hyperimmunized with the Pgh 3-2 pilus vaccine. The mean pre-immunization antipilus LPS antibody level was 0.53 ug/ml and the 6-wk mean post-immunization level was 5.6 ,ug/ml which constituted a 10-fold rise, while the mean pre-immunization antipilus antibody level of 0.34 ,ug/ ml and the 6-wk post-immunization level of 660 ,ug/ml which constituted a 1,320-fold antibody rise. The seven human laboratory volunteers who had received 1,000-,ug vaccine doses were also tested. They were found to have had an average of 0.42 ug/ml of pre-vaccination anti-LPS antibody and a mean peak of 0.62 gg/ml of post-vaccination anti-LPS antibody at 2 wk, which is a small antibody increase. However, all ofthe volunteers had an increase in anti-LPS antibody suggesting an immunologic response, albeit slight, to the contaminating LPS (Table IV) . These small antibody increases were of the IgG immunoglobulin class only. Because this slight antibody increase may have been due to a nonspecific polyclonal antibody response, competitive inhibition of the anti-LPS antibody was done usiIng the degree of crossreactivity. Individuals from the purified Pgh 3-2 gonococcal LPS. The antibody bind-different dosage groups were randomlynI chosen and the ing was blocked and therefore was shown to be specific geometric mean fold rise was calculated (Table V) . for the vaccine strain of LPS. Every individual had a specific rise to each heterologous The antisera were also assayed for pilus specific pili but the individual variation was great. The range antibodies against three heterologous pili to determine tended to lessen after the booster dose was given and 2-and 6-wk post-immunization sera were tested in the SPRIA. The booster vaccination wvas given at the 4th wk. The number of individuals in each group were chosen at random. Pgh 3-2 pili were the homologous vaccine pili. reduced the IEA titer to its preimmunization level (Table VII) . Adsorption with LPS slightly reduced the amount of antibody binding to the vaccine pilus preparation.
Because of the importance of crossreactivity against heterologous strains, sera from three volunteers were tested for IEA antibody rises against eight heterologous strains. An increase in IEA antibody titer was demonstrated against all of the heterologous strains (12 determinations). However, half of the titer rises (six) were of a small magnitude (Table VIII) .
To determine whether the IEA antibody against the heterologous pili might be directed at a common determinant(s) on each pilus strain, sera was adsorbed with one heterologous pili and tested against different strains. Adsorption reduced the IEA titer against all three of the heterologous strains to pre-immunization levels (Table IX) .
DISCUSSION
The Pgh 3-2 gonococcal pilus vaccine was shown to be safe and well tolerated. No serious adverse reactions occurred. The most common complaint was that of a sore arm and this correlated with the volume of material injected, although subjectively, the degree of soreness appeared to be greatest in those receiving the vaccine.
The Pgh 3-2 gonococcal pilus vaccine was found to be antigenic. Parenteral administration of the vaccine produced a serum antibody response in the three principal immunoglobulin classes in all volunteers tested with the SPRIA. The antibody rise to the homologous pili generally correlated with the amount of antigen (pilus vaccine) given. The booster vaccination tended to raise the antibody level of the low responders but did not appreciably boost those who had had a good initial response.
The antipilus antibody was also capable of functional activity, namely IEA. It is theorized that this is at least one of the means by which this antibody might function to protect the host (17, 18, 27 There was an antibody increase to the three heterologous pili tested. This supports the results of previous studies which demonstrated that adsorption with one heterologous pilus preparation removed all ofthe crossreactive antibody to other heterologous pili (6) . Furthermore, all of the crossreactive IEA antibody in one serum was also removed by adsorption with a heterologous pilus, suggesting that the crossreactive pilus antibody is directed at a common determinant(s) ( Table IX) .
The recidivistic nature of gonococcal infections would suggest that immunity to gonorrhea does not always develop. There is evidence to suggest that this may be due to a poor immune response, a short-lived immune response and/or antigenic variation among strains of gonococci. However, this should not discourage attempts to stimulate an effective immune response by vaccination as a possible means of controlling this disease. Furthermore, cross reacting antibody to heterologous gonococcal pili and gonococcal strains, a prerequisite for vaccine efficacy, has been demonstrated.
A prototype E. coli pilus vaccine has been shown to protect piglets that had been given colostrum from sows parenterally immunized with E. coli pili (28, 29) . The efficacy of the gonococcal pilus vaccine must await clinical field trials.
